PKLR

Across TCGA pan-cancer cohorts, PKLR mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PKLR’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where PKLR mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PKLR is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and COAD are the cancer types where PKLR tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PKLR mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−1.711	<.001	9	view →
LUAD	Female	III,IV	−1.695	<.001	9	view →
COAD	All	III,IV	−1.240	<.001	9	view →
CCRCC	Male	All	−0.816	<.001	9	view →
HNSC	Male	All	−1.049	<.001	8	view →
PDAC	Male	III,IV	−1.458	.008	6	view →
OV	All	All	−1.351	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PKLR–LSCC

Open the LSCC breakdown →